glp-1/gcgr dual agonist GCGR: A Key Target in Glucose Metabolism-DIMA BIOTECH GIPR/GLP-1R dual agonist therapies for
Description
The ReduCore formula doesnt contain immune enhancing doses
2012;303:E25364
A double-blind, randomized trial of 750 women with anovulatory PCOS reported 27.5% cumulative live birth rates for woman on letrozole vs 19.1% for women on clomiphene
High-dose ACEI with DPP-4i may diminish the effect of anti-hypertensive drugs due to increased sympathetic activation, while low-dose ACEI has no such effect
This could explain why tirzepatide (which stimulates the GIP pathway in addition to GLP -1) can be administered at higher doses than semaglutide (which only stimulates GLP-1), without amplifying the side effects typical of GLP-1 agonists (nausea, vomiting)
doi: 10.1016/j.peptides.2017.11.017
